OC-0065: Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for NSCLC: experience from nine UK centres

Continuous hyperfractionated accelerated radiotherapy – Escalated dose (CHART-ED): A phase I study

“…These accelerated 'conventional' treatments also report good local control in stage I disease with a local relapse figure of 13%, and we should remember the median survival of 25.2 months documented for CHART treatment of stage 1A and 1B disease 23 is consistent with that reported in these publications. The significant toxicities seen when SABR was used for more central tumours 16 is an additional reason to continue to develop accelerated schedules for the treatment of stage III disease where mediastinal radiotherapy will need to be given.…”